A prospective study of peri-transplant sorafenib for FLT3-ITD AML patients undergoing allogeneic transplantation

FLT3-ITD mutated AML is rarely cured with chemotherapy alone [1]. Current approaches incorporate allogeneic hematopoietic stem cell transplant (HSCT) in first remission for those patients who have a suitable donor and are medically qualified for transplantation [2]. Specific targeting of the oncogenic FLT3-ITD receptor to maintain remission before and after HSCT represents one avenue yet to be prospectively evaluated to improve this poor prognosis subset. Early in the post transplant period may be a unique setting to enhance the activity of targeted agents.

Source: Biology of Blood and Marrow Transplantation - September 20, 2019 Category: Hematology Authors: Keith W Pratz, Michelle A Rudek, B. Douglas Smith, Judith Karp, Ivana Gojo, Amy Dezern, Richard J Jones, Jackie Greer, Christopher Gocke, Maria R Baer, Vu H Duong, Gary Rosner, Marianna Zahurak, John J Wright, Ashkan Emadi, Mark Levis, ETCTN-8922 study te Source Type: research